173 related articles for article (PubMed ID: 35856818)
1. A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants.
Wainwright CE
Am J Respir Crit Care Med; 2022 Nov; 206(10):1193-1195. PubMed ID: 35856818
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
3. COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No.
Thursfield RM; Shafi N; Davies JC
Chest; 2022 Jan; 161(1):21-24. PubMed ID: 35000702
[No Abstract] [Full Text] [Related]
4. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
5. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
6. SIMPLIFYing cystic fibrosis treatment in a post-modulator era.
Yang C
Lancet Respir Med; 2023 Apr; 11(4):299-300. PubMed ID: 36463912
[No Abstract] [Full Text] [Related]
7. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
[No Abstract] [Full Text] [Related]
8. Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function.
Massie J; Castellani C; Grody WW
Lancet; 2014 Mar; 383(9920):923-5. PubMed ID: 23992917
[No Abstract] [Full Text] [Related]
9. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
10. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
11. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
12. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
13. Overcoming health disparities in access to CFTR modulator therapies: One child's journey with cystic fibrosis.
Januska MN; Langfelder-Schwind E; Berdella MN
Pediatr Pulmonol; 2022 Sep; 57(9):2273-2275. PubMed ID: 35637164
[No Abstract] [Full Text] [Related]
14. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
[No Abstract] [Full Text] [Related]
15. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
[No Abstract] [Full Text] [Related]
16. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.
Hull J
J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S2-8. PubMed ID: 22688363
[No Abstract] [Full Text] [Related]
18. Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor.
Smith H; Rayment JH
Pediatr Pulmonol; 2020 Oct; 55(10):2493-2494. PubMed ID: 32678518
[No Abstract] [Full Text] [Related]
19. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
[No Abstract] [Full Text] [Related]
20. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.
Lahiri T; Sullivan JS
Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
